| Code | CSB-RA004847MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BGB-A3055, targeting CCR8 (C-C chemokine receptor type 8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a critical role in immune cell trafficking to inflammatory sites and the tumor microenvironment. This receptor has emerged as a promising therapeutic target in immuno-oncology, as CCR8-expressing Tregs within tumors contribute to immunosuppression and tumor immune evasion across multiple cancer types, including colorectal, breast, and lung cancers.
BGB-A3055 is an investigational anti-CCR8 antibody designed to selectively deplete tumor-infiltrating Tregs while sparing peripheral Tregs, potentially enhancing anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating CCR8 biology, Treg function in tumor immunity, and mechanisms of immune regulation. It supports studies exploring novel immunotherapeutic strategies and biomarker discovery in cancer research, as well as investigations into inflammatory and autoimmune disease mechanisms.
There are currently no reviews for this product.